Nuwellis, Inc. (NASDAQ:NUWE – Get Free Report) saw a significant growth in short interest during the month of October. As of October 30th, there was short interest totaling 195,586 shares, a growth of 118.9% from the October 15th total of 89,357 shares. Based on an average daily volume of 3,723,204 shares, the days-to-cover ratio is currently 0.1 days. Approximately 36.8% of the shares of the company are sold short.
Analyst Ratings Changes
Several equities research analysts recently issued reports on the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Nuwellis in a research note on Monday, September 21st. Wall Street Zen lowered Nuwellis from a “hold” rating to a “sell” rating in a research note on Saturday. One equities research analyst has rated the stock with a Sell rating. According to data from MarketBeat, Nuwellis presently has a consensus rating of “Sell”.
Check Out Our Latest Report on Nuwellis
Nuwellis Stock Down 2.1%
NASDAQ NUWE traded down $0.10 on Monday, hitting $4.79. The company’s stock had a trading volume of 4,976 shares, compared to its average volume of 337,937. Nuwellis has a 1-year low of $2.52 and a 1-year high of $1,556.07. The company’s 50-day moving average is $6.03 and its 200 day moving average is $206.53. The firm has a market cap of $2.59 million, a PE ratio of -0.00 and a beta of 0.03.
Nuwellis (NASDAQ:NUWE – Get Free Report) last posted its quarterly earnings data on Thursday, November 12th. The company reported ($5.81) EPS for the quarter, topping analysts’ consensus estimates of ($122.85) by $117.04. The company had revenue of $2.21 million for the quarter, compared to analyst estimates of $2.50 million. Nuwellis had a negative return on equity of 414.75% and a negative net margin of 150.50%.
About Nuwellis
Nuwellis, Inc. is a medical technology company focused on fluid management for patients with fluid overload. The company develops and markets the Aquadex SmartFlow system, which uses ultrafiltration to remove excess fluid and is used by healthcare professionals in hospital settings. Aquadex includes a device and disposable components designed to support controlled fluid removal. It is intended for use in adults and children with fluid overload, including patients who may not respond adequately to diuretic therapy.
Featured Articles
- Five stocks we like better than Nuwellis
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
- Embraer’s Record Backlog Looks Promising, But Can It Keep Its Margins Climbing?
- Could Big Buybacks Be the Next Catalyst for These 3 AI Stocks?
Receive News & Ratings for Nuwellis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuwellis and related companies with MarketBeat.com's FREE daily email newsletter.
